Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


STADA Arzneimittel AG

Latest From STADA Arzneimittel AG

Stada Tight-Lipped On Potential Sale Amid Reports Talks Are Underway

The rumor mill is heating up on Stada’s potential sale by its owners, Bain Capital and Cinven, after seven years at the helm.

Deals Companies

Is Stada Laying The Ground For Future Sale With Russia Business Spin Off?

With the war in Ukraine now in its third gruelling year, Stada has announced that it last year siphoned off its Russian interests to its parent company Nidda in a non-cash deal.

Deals M & A

Stada And Alvotech Eye Launch Date For Ustekinumab After EU Approval

Stada has revealed details of exactly when in 2024 it plans to launch its Alvotech-partnered Uzpruvo ustekinumab biosimilar to Stelara, having just been granted a pan-European marketing authorization. At the same time, the German firm has also struck a distribution deal for prescription and consumer healthcare products with Zuellig in the Philippines.

Biosimilars Approvals

Big Pharma Shouts, Generics And Biosimilars Whisper: M&A In 2023

“A lot of companies are hurting because of the higher interest rates,” one major CEO observed recently, summing up a year which saw little headline-grabbing news on the M&A front for generic and biosimilar sponsors.

M & A Deals
See All

Company Information